News

Type 1 diabetes deadlier in women


 

References

Women with type 1 diabetes have a much higher risk of death from all causes than do men with type 1 diabetes, according to Dr. Rachel Huxley and her associates.

Volkan Ünalan/Thinkstock.com

The systematic review of studies published during 1966-2014 showed that the biggest differences were in vascular diseases, with coronary heart diseases occurring in women 2.5 times more often than in men and fatal cardiovascular events occurring nearly twice as often. Stroke and fatal renal disease occurred about 40% more often in women. No significant difference was found for cancer or for accidents and suicides. Overall, fatal events were 37% more likely in women with type 1 diabetes than in men.

In a related comment, Dr. David Simmons of the University of Western Sydney (Australia) said, “A key question is how the risk of excess mortality in women can be reduced further. Reducing the high type 1 diabetes mortality rates will need additional expenditure on the care of patients with the disorder, many of the benefits from which might not be seen for up to 20 years. The additional investment in the diabetes specialist and mental health services to be able to give the additional time that patients need, and into modern technology that can help reduce hyperglycemia while avoiding hypoglycemia and fear of hypoglycemia, must start now.”

Read the full study at the Lancet Diabetes and Endocrinology (doi:10.1016/S2213-8587(14)70248-7).

Recommended Reading

Diabetes substantially overtreated in older adults
MDedge Endocrinology
FDA approves vagal blocking device for obesity
MDedge Endocrinology
HF: Glucose at ED presentation may predict mortality
MDedge Endocrinology
Zero coronary calcium means very low 10-year event risk
MDedge Endocrinology
Lower diabetes risk seen in lupus patients using hydroxychloroquine
MDedge Endocrinology
FDA approves mobile medical app for real-time sharing of glucose data
MDedge Endocrinology
Metformin linked to lower risk of lung cancer in diabetic nonsmokers
MDedge Endocrinology
Overtreatment of diabetes
MDedge Endocrinology
FDA approves empagliflozin-linagliptin combo tablet
MDedge Endocrinology
Breast cancer patients show poor adherence to cardiovascular, diabetes medications
MDedge Endocrinology